Ryan Preblick - Indivior PLC CFO Director
| IZQVFDelisted Stock | USD 23.94 0.35 1.44% |
Insider
Ryan Preblick is CFO Director of Indivior PLC
| Phone | 804 379 1090 |
| Web | https://www.indivior.com |
Indivior PLC Management Efficiency
The company has return on total asset (ROA) of 0.0697 % which means that it generated a profit of $0.0697 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.8557 %, meaning that it generated $0.8557 on every $100 dollars invested by stockholders. Indivior PLC's management efficiency ratios could be used to measure how well Indivior PLC manages its routine affairs as well as how well it operates its assets and liabilities.Indivior PLC has accumulated 239 M in total debt with debt to equity ratio (D/E) of 1.22, which is about average as compared to similar companies. Indivior PLC has a current ratio of 1.67, which is within standard range for the sector. Debt can assist Indivior PLC until it has trouble settling it off, either with new capital or with free cash flow. So, Indivior PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Indivior PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Indivior to invest in growth at high rates of return. When we think about Indivior PLC's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Mximo Juda | Genomma Lab Internacional | N/A | |
| Thomas Harvey | Alkermes Plc | N/A | |
| Joao Aguilar | Hypera SA | N/A | |
| Engineer Galland | Genomma Lab Internacional | N/A | |
| Efran Crdova | Genomma Lab Internacional | N/A | |
| Hlio Segouras | Hypera SA | N/A | |
| Keith Katkin | Emergent Biosolutions | 48 | |
| Robert Sr | Emergent Biosolutions | 67 | |
| Juliana Salem | Hypera SA | N/A | |
| Juan Sparvieri | Genomma Lab Internacional | N/A | |
| Alejandro Patio | Genomma Lab Internacional | N/A | |
| Cindy Patton | Cumberland Pharmaceuticals | 71 | |
| Lynn Kieffer | Emergent Biosolutions | N/A | |
| L Porres | Genomma Lab Internacional | N/A | |
| Adam Mostafa | Cumberland Pharmaceuticals | 44 | |
| Daniel Neria | Genomma Lab Internacional | N/A | |
| Marianne Velasco | Genomma Lab Internacional | N/A | |
| Jennifer Fox | Emergent Biosolutions | 51 | |
| Adalmario Couto | Hypera SA | N/A | |
| Jorge Valderrama | Genomma Lab Internacional | N/A | |
| Luiz Clavis | Hypera SA | N/A | |
Management Performance
| Return On Equity | 0.86 | |||
| Return On Asset | 0.0697 |
Indivior PLC Leadership Team
Elected by the shareholders, the Indivior PLC's board of directors comprises two types of representatives: Indivior PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Indivior. The board's role is to monitor Indivior PLC's management team and ensure that shareholders' interests are well served. Indivior PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Indivior PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jon Fogle, Chief Human Resource Officer | ||
| Nina DeLorenzo, Chief Officer | ||
| Jeffrey Burris, Chief Officer | ||
| Jason Thompson, VP Relations | ||
| Christian Heidbreder, Chief Scientific Officer and Head of RandD | ||
| Richard Simkin, Chief Commercial and Strategy Officer | ||
| Ryan Preblick, CFO Director | ||
| Mark Crossley, CFO, Director | ||
| Hillel West, Chief Officer | ||
| Cynthia Cetani, Chief Officer |
Indivior Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Indivior PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.86 | |||
| Return On Asset | 0.0697 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 2.39 B | |||
| Shares Outstanding | 136.2 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 61.97 % | |||
| Price To Earning | 158.41 X | |||
| Price To Book | 13.24 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Indivior Pink Sheet
If you are still planning to invest in Indivior PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Indivior PLC's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |